Cellectar Biosciences Inc
CLRB
View Detailed Chart
5.200USD
-0.290-5.28%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
9.42MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.28%
5 Days
+2.36%
1 Month
+15.56%
6 Months
+1248.20%
Year to Date
+1639.13%
1 Year
+146.45%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
84.000
Target Price
+1430.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 55.87.
Fairly Valued
The company’s latest PE is -0.28, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 195.80K shares, decreasing 64.42% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 56.34K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.95.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Ticker SymbolCLRB
CompanyCellectar Biosciences Inc
CEOMr. James V. Caruso
Websitehttps://www.cellectar.com/
Related Instruments
-1.43%
+1.17%
+0.22%
+0.52%
-1.03%
-0.73%
-0.02%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.27%
+1.19%
+0.92%
-0.87%
-0.23%
-0.83%
-1.12%
+0.31%
